EMERGING RESEARCHER APPOINTED TO JAMES PACKER CHAIR IN MOOD DISORDERS AT UNSW Joins department with over 60 years research in Psychiatry and Mental Health to investigate Bipolar Disorder
The UNSW Discipline of Psychiatry and Mental Health is widely renowned as the pre-eminent psychiatry research department in the country and one of the leading university psychiatry research groups internationally. In 2023 it celebrated 60 Years of Psychiatry & Mental Health at UNSW Sydney.
Australian Health Journal spoke with Professor Kimberlie Dean, Head of the Discipline of Psychiatry and Mental Health at UNSW Sydney, about the recent appointment of mental health disorders expert and clinician researcher Dr Aswin Ratheesh to lead the James Packer Chair in Mood Disorders at UNSW Sydney.
Professor Dean spoke about UNSW being home to an outstanding mental health research community with key partners across the Mindgardens Neuroscience Network, welcoming Dr Ratheesh
As a leading clinical researcher in mood and psychotic disorders, Dr Ratheesh is passionate about prompt and early access to interventions for people with such conditions.
The appointment comes after prominent businessman and investor James Packer, jointly with The Packer Family Foundation, made a $7 million gift to establish the role last year.
The Chair will lead a new unit at UNSW and the Mindgardens Neuroscience Network that will conduct rigorous research in mental health, with a particular focus on mood disorders such as bipolar disease. The gift also funds a team of researchers to support the Chair.
Dr Ratheesh’s research is focused on understanding pathways leading to the onset of mood disorders and finding ways to provide effective treatments for individuals who develop such conditions. He has worked as a psychiatrist for over 12 years both in youth and adult mental health settings and has led several studies that have helped identify risk markers for future bipolar disorder.
He believes some of the current knowledge gaps in mood disorders include our ability to predict who will develop such conditions, who is at risk of worsening, and who will respond to specific treatments.
Dr Ratheesh currently leads an NHMRC Partnership grant in early intervention for bipolar disorder and is a chief investigator on a Centre of Research Excellence grant in early intervention for bipolar disorder. He co-leads the International Society of Bipolar Disorders Taskforce on Early Intervention and is an Associate Editor for the leading journal, the Australian and New Zealand Journal of Psychiatry. He has received awards from the International Early Psychosis Association and the Australasian Society for Bipolar and Depressive Disorders for his research.
-
Global MedTech company brings device reprocessing plant to Australia
Cardinal Health is global medical products manufacturer and leading provider of single-use device reprocessing services in the U.S. In Australia and New Zealand, as one of the largest suppliers of medical devices, announced on 23 May 2024 that it will be opening a single-use medical device reprocessing facility in Australia – its first reprocessing facility outside the United States.
On 18 March 2025 at the Health Innovation Living Lab at the John Hunter Hospital, a further announcement was made, on the chosen single-use medical device remanufacturing facility in Beresfield, Newcastle, set to commence operation late 2025, supported by the NSW Department of Primary Industries and Regional Development.
-
Developing the nation’s first Health and Medical Research Strategy
Professor Steve Wesselingh serves as the CEO of NHMRC, having initially trained as an infectious diseases doctor. His career includes prominent roles such as Head of the Infectious Diseases Unit at the Alfred Hospital, Director of the Burnett, Dean of Medicine at Monash University, and the inaugural Director of SAHMRI. Under his leadership, NHMRC plays a critical role in funding health and medical research, allocating approximately a billion dollars annually to investigator-led projects, clinical trials, and various strategic initiatives. NHMRC also collaborates internationally with organisations such as the MRC and the EU, and manages grant allocation for the MRFF, which distributes $650 million each year.
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
